UnitedHealthcare (UHC), one of the nation’s largest health insurers, has announced an updated policy change regarding coverage for remote patient monitoring services. As of the latest update, UHC will end coverage for most remote patient monitoring (RPM) when it is determined to be “unproven and not medically necessary,” specifically targeting standard cases of Type 2 diabetes and hypertension. This decision has broad implications for healthcare professionals, patients, and those tracking healthcare policy developments.
UHC’s new policy discontinues coverage for remote patient monitoring in cases where the service is considered unproven or not medically necessary, focusing chiefly on routine management of Type 2 diabetes and most hypertension cases. However, there are notable exceptions:
These exceptions underscore UHC’s commitment to supporting RPM where research demonstrates clear clinical value. The policy applies to new and existing patients as of the effective date, which is detailed in UHC’s provider communications.
The policy affects UHC members across several plan types, including those enrolled in Medicare Advantage, commercial employer-sponsored insurance, individual exchange (Marketplace) plans, and Medicaid. For most individuals with Type 2 diabetes or standard hypertension, remote monitoring devices and associated services will no longer be reimbursed unless a specific exception applies. Providers and patients should carefully review plan details to understand ongoing eligibility and coverage for RPM.
The Centers for Medicare & Medicaid Services (CMS) is expected to implement new rules that adjust payment rates for remote patient monitoring services in 2025. These changes may influence how payers and providers structure RPM programs and could impact future coverage decisions. Stakeholders are watching closely to understand how these federal updates will interact with insurer policies like UHC’s.
UnitedHealthcare’s revised remote patient monitoring policy marks a notable shift in coverage for chronic disease management. While the decision narrows access for many with Type 2 diabetes and hypertension, it maintains support for populations where RPM has proven benefits. As CMS finalizes new rules and advocacy groups push for policy reconsideration, patients and providers should stay informed about coverage updates and seek guidance to ensure continuity of care where remote monitoring remains essential.